$21.12
▼ -1.0% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Innoviva to Participate in Upcoming Investor Conferences
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
Overview
52-week range
$17
$25
53% of range
Avg surprise (last 2)
+18.7%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
86%
EM ±13.5% · $20 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.14 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.44 | $0.43 | +2.3% | +76.0% | -0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.08 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.77 | $0.57 | +35.1% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.25 | — | — | — | +0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.55 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.46 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.98 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.02 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.42 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $120M | $98M | — | $108M | $100M | $89M | — | $90M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $91M | $76M | — | $76M | $83M | $73M | — | $73M |
| Operating income | $51M | $38M | — | $35M | $49M | $41M | — | $43M |
| Net income | $-83M | $187M | — | $90M | $64M | $-47M | — | $1M |
| EPS (diluted) | $-1.14 | $2.22 | — | $1.08 | $0.77 | $-0.74 | — | $0.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $570M | $603M | $551M | $477M | $398M | $319M | $305M | $261M |
| Inventory | $39M | $39M | $39M | $38M | $49M | $41M | $34M | $34M |
| Total current assets | $753M | $773M | $728M | $685M | $652M | $582M | $554M | $401M |
| Total assets | $1.70B | $1.84B | $1.64B | $1.43B | $1.33B | $1.25B | $1.30B | $1.23B |
| Long-term debt | $258M | $258M | $258M | $257M | $257M | $257M | $256M | $256M |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $1.23B | $1.34B | $1.17B | $1.01B | $715M | $647M | — | $669M |